 (J Occup Environ Med. 2004;46:584 -590) 
L ead exposure has been associated with increased blood pressure in some, but not all, studies in humans. [1] [2] [3] [4] [5] [6] [7] [8] [9] Overall, the body of epidemiologic literature would support the inference that lead causes elevations in blood pressure, even at relatively low levels. In addition to the epidemiologic evidence, there is evidence from animal models, because animals fed lead have elevations in blood pressure. 10 Some evidence suggests that lead could increase blood pressure by lowering steadystate levels of nitric oxide (NO), [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] a principal endothelium-derived relaxing factor and one of the body's key modulators of vascular resistance. [23] [24] [25] [26] Constitutively produced in the endothelium by endothelial nitric oxide synthase (eNOS), NO diffuses into the vascular wall to relax the vascular smooth muscle. Animal and human studies unequivocally demonstrate that reduced steady-state NO levels substantially increase blood pressure. [27] [28] [29] [30] Lead could increase blood pressure either through decreasing production of NO and/or increasing NO inactivation.
Polymorphisms in the gene for eNOS have been suggested to be susceptibility factors for hypertension, with a G 894 -T 894 nucleotide substitution polymorphism in exon 7 receiving much recent attention. The T 894 allele, the minor allele, is prevalent at 10% to 40% (depending on the population sampled) 31 ; studies in Asian populations, mainly from Japan, have reported T 894 allele prevalences of 5% to 9%. 31, 33, 37, 39 Some studies indicate that the T 894 allele is associated with increased blood pressure and decreased production of NO; other studies provide conflicting evidence. In the current study, we describe the association of the T 894 allele with blood pressure and evaluate whether the allele modifies the association of lead with blood pressure in a cohort of 803 lead-exposed workers from Korea. The associations of lead with systolic and diastolic blood pressure and hypertension have been previously reported in this population. 54 Many mechanisms have been proposed for how lead could increase blood pressure; it is important to evaluate gene-environment interaction, like we have here, because if eNOS genotype does not modify the relation of lead dose with blood pressure, this provides evidence that lead is unlikely to act through the eNOS gene product to influence blood pressure. Such studies thus have relevance for understanding the mechanism of lead toxicity.
Materials and Methods

Parent Study
The study population and design have been previously described. 54 -57 The study was reviewed and approved by Institutional Review Boards at The Johns Hopkins Bloomberg School of Public Health and Soonchunhyang University School of Medicine. In brief, individuals from this cohort were recruited as part of a 3-year longitudinal study of lead-exposed workers and nonexposed control subjects without occupational lead exposure. Enrollment for the longitudinal study began in October 1997 and ended in August 1999. A total of 803 leadexposed workers were recruited. Participation in the study was voluntary and subjects were paid approximately $30 US for their time and effort. Participants in this study provided written informed consent. Participation rates by plant generally exceeded 80%. No medical exclusionary criteria (eg, blood pressure, renal disease) were applied. Government-mandated industrial hygiene surveillance indicated that the leadexposed workers were not exposed to significant levels of other heavy metals such as cadmium, which affect health.
Several assessments were made for individuals in this cohort, including: 1) a standardized questionnaire for information such as age, gender, education, smoking history, alcohol consumption, health history, and occupational history; 2) measurement of blood pressure, height, and weight; 3) measurement of tibia lead in micrograms of lead per gram of bone mineral by 109 Cd-based K-shell x-ray fluorescence (XRF); and 4) measurement of whole blood lead (g/dL) with a Zeeman backgroundcorrected atomic absorption spectrophotometer (Hitachi Z-8100 model). Details of the data collection procedures have been previously published. 54 -57 Blood pressure, systolic and fifth Korotkoff diastolic, was measured using a Hawksley random zero sphygmomanometer using The Johns Hopkins Welch Center for Prevention, Epidemiology, and Clinical Trials protocol. Three measurements, using an appropriately sized cuff, were taken by a physician trained in the method 5 minutes apart with the subject sitting.
Genotyping Assays
Genomic DNA for the assay was isolated from whole blood samples provided by the study participants, as previously described. 54 A polymerase chain reaction (PCR)-based assay was adapted from Hibi et al. to genotype individuals for the polymorphism. 58 The primer sequences were 5Ј-TCCCTGAGGAGGGCAT-GAGGC T-3Ј and 5Ј-TGAGGGT-CACACAGGTTCCT-3Ј. The PCR resulted in a 457-bp product. Ban II restriction enzyme digest was used to distinguish genotypes. Digest with Ban II cleaved the G 894 variant PCR product into 2 fragments (of size 137 bp and 320 bp). The T 894 variant PCR product did not have a Ban II restriction site. These fragments were resolved on a 1.5% agarose gel and stained with ethidium bromide. Individuals could be homozygous GG (in which case a 137-bp band and a 320-bp band appeared on the gel), homozygous TT (only a single 457-bp band appeared on the gel), or heterozygous TG (all 3 bands appeared on the gel). In 803 samples, we were able to successfully genotype 793 individuals. Control samples were sequenced to verify genotypes. All TG heterozygotes and TT homozygotes were repeated to confirm genotype. Samples were evaluated blinded to blood pressure or lead levels.
Statistical Analysis
The purpose of the statistical analysis was to model the association of the T 894 allele with blood pressure and to evaluate whether the allele (TG heterozygotes or TT homozygotes) modified associations of lead dose with blood pressure. Linear regression was used to model systolic blood pressure and diastolic blood pressure. Logistic regression was used to model hypertension, which was defined by a systolic blood pressure Ն140 mm Hg, a diastolic blood pressure Ն90 mm Hg, or reported use of medication for hypertension.
The following covariates were included in the models: age, gender, body mass index (BMI; kg/m 2 ), smoking, alcohol consumption, high school education, tibia lead, blood lead, and job duration. Because lead has a clearance half-time of approximately 30 days in blood, blood lead is more reflective of recent exposures, although bone lead stores can also contribute to blood levels. In contrast, lead has a clearance halftime of approximately 25 to 30 years in tibia, so tibia lead is a measure of retained cumulative dose. All covariates were retained in the final model. In the regression models, smoking was represented as lifetime nonsmoking, quit smoking, smoking Ն1 pack/day, and smoking Ͻ1 pack/day. Alcohol consumption was represented as no current consumption, Ͻ1 drink/day, or Ն1 drink/day. In models of systolic blood pressure, age was represented as a spline, with a change point at 45 years, because of the nonlinear relation with age.
Tibia lead and blood lead were represented by percentiles (rank/total N) in the regression models to allow direct comparability of the 2 biomarkers of lead exposure. This approach mitigated concerns about influential points, resulting from very high blood lead or tibia lead values. Only points with missing values were excluded from the regression analyses. Regression coefficients (Ϯ standard error) are expressed as mm Hg/decile increase in lead. The interaction of lead and genotype in models of blood pressure was evaluated as the product of main effects (lead * genotype). To allow for the nonlinear association of lead and blood pressure, second-order interaction terms were evaluated (lead 2 * genotype). The multiple partial F test was used to evaluate the combination of the first-and second-order interaction terms.
Genotype-stratified loess lines were generated to graphically compare plots of the adjusted blood pressure versus adjusted lead associations by genotype. Adjusted values were obtained from regression models for blood pressure and lead, adding the mean value of covariates to the regression residuals to obtain adjusted blood pressure and adjusted lead. All analyses were conducted using SAS release 6.12 (SAS Institute, Inc., Cary, NC).
Results
The genotype distributions were 85% (673 of 793) GG, 14% (114 of 793) TG, and 1% (6 of 793) TT. The overall frequency of the T 894 allele was 8% (126 of 1586). The distributions of age, gender, body mass index, smoking, alcohol consumption, education, tibia lead, blood lead, and duration of employment were similar in individuals with and without the T 894 allele (Table 1) . Individuals with the T 894 allele had similar mean (Ϯ standard deviation) systolic blood pressure (-0.77 Ϯ 1.62 mm Hg, P ϭ 0.6), mean diastolic blood pressure (-0.01 Ϯ 1.19 mm Hg, P ϭ 0.9), and odds of hypertension (OR ϭ 0.82; 95% CI ϭ 0.50 -1.37; P ϭ 0.4) compared with those without the variant allele. Adjustment for age, gender, BMI, smoking, alcohol consumption, high school education, tibia lead, blood lead, and job duration did not substantially alter the parameter estimates ( Table 2 ).
The associations of tibia lead and systolic blood pressure were similar in individuals with and without the T 894 allele ( Fig. 1 ; Table 3 ). Tibia lead was associated with an adjusted 0.63 Ϯ 0.21 mm Hg/decile increase in systolic blood pressure (P ϭ 0.003) in GG homozygotes and an adjusted 0.48 Ϯ 0.51 mm Hg/decile increase in systolic blood pressure (P ϭ 0.3) in TG/TT individuals. The interaction of genotype and tibia lead (modeled as tibia lead percentile as a continuous variable in the regression) was not statistically significant (P ϭ 0.8 for the product of the main effects, genotype * tibia lead). Higher-order interaction terms (eg, genotype * tibia lead-squared) were not statistically significant (P ϭ 0.3 in a model with a first-order interaction term). First-order and second-order interaction terms of genotype and tibia lead did not significantly improve the fit of the model when evaluated together (P ϭ 0.8)
The association of blood lead and systolic blood pressure was similar in individuals with and without the T 894 allele ( Fig. 2 ; Table 3 ). Blood lead was associated with an adjusted 0.43 Ϯ 0.23 mm Hg/decile increase in systolic blood pressure (P ϭ 0.06) in GG homozygotes and an adjusted 0.40 Ϯ 0.49 mm Hg/decile increase in systolic blood pressure (P ϭ 0.4) in TG/TT individuals. The interaction of genotype and blood lead (representing blood lead percentile as a continuous variable in the regression) was not statistically significant (P ϭ 0.9 for the product of main effects, genotype * blood lead). Higher-order interaction terms (eg, genotype * blood lead-squared) were not statistically significant (P ϭ 0.9 in a model with a first-order interaction term). First-order and secondorder interaction terms of genotype and blood lead did not significantly improve the fit of the model when evaluated together (P ϭ 0.9). Tibia lead and blood lead were not associated with diastolic blood pressure in individuals with or without the T 894 allele (data not shown).
Discussion
The T 894 Allele and Blood Pressure
Overall, the T 894 allele was not associated with systolic blood pressure, diastolic blood pressure, or odds of hypertension. The differences in mean systolic and diastolic blood pressure between the groups were small. Taking GG homozygotes as a reference, the difference in mean systolic blood pressure was -0.77 Ϯ 1.62 mm Hg and the difference in mean diastolic blood pressure the difference was -0.01 Ϯ 1.19 mm Hg. The prevalence of hypertension between the two groups was similar (OR ϭ 0.82; 95% CI ϭ 0.50 -1.37 taking TG/TT relative to GG).
No clear consensus on the association of hypertension and the G 894 -T 894 polymorphism emerges from the literature. Some groups report that the T 894 allele is more frequent in individuals with hypertension; other groups report conflicting findings. [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] 59, 60 The current study is consistent with reports indicating no association of the T 894 allele with hypertension.
The reasons for the different results obtained across studies are unclear, but we offer the following possible explanations: 1) The G 894 -T 894 locus is a marker for functional polymorphisms at other genetic loci. In some populations, the T 894 allele could be in linkage disequilibrium with a genetic polymorphism that * Model included terms for age, gender, body mass index (ln-transformed), reported smoking (nonsmoking, ϭ 1 pack/day, Ͼ1 pack/day, former smoking), current reported alcohol consumption (none ϭ 1 drink/day, Ͼ1 drink/day), education (high school-educated), and job duration.
† Regression coefficients generated from one model with interaction terms with genotype and lead. does have an effect on blood pressure, whereas in other populations, no linkage may be present. Allelic association within polymorphic loci of eNOS has been documented in several reports. 31, 39, [61] [62] [63] 2) Diverse genetic, dietary, and environmental factors could substantially modify the association of the polymorphism and hypertension. In some populations, these factors could be present, and in other populations, they could be absent. 3) In some populations, decreased NO production might not be a factor in the development of hypertension; responsiveness to existing levels of NO could be decreased, NO inactivation could be increased, or processes totally unrelated to the NO system could increase blood pressure. Measures of NO production have been reported to be decreased, unchanged, and even increased in hypertension. 64 -75 If decreased NO production was not involved in the development of hypertension, then polymorphisms in the gene for eNOS would not be expected to be risk factors for hypertension.
The T 894 Allele and the LeadBlood Pressure Association
There was no evidence that the T 894 allele modified associations of lead with blood pressure. A comparison of loess lines indicates a similar association of adjusted systolic blood pressure and adjusted tibia lead in individuals with and without the T 894 allele. Tibia lead was not associated with diastolic blood pressure in the cohort overall, or in individuals with or without the allele.
Individuals with the T 894 allele were not more sensitive to the effects of blood lead on systolic blood pressure either. As a comparison of loess lines indicates, above the 50th percentile of blood lead, individuals with the T 894 allele had a similar association of blood lead and systolic blood pressure as GG homozygotes. Below the 50th percentile blood lead, adjusted systolic blood pressure was not associated with adjusted blood lead in the cohort as a whole. The loess lines for GG homozygotes and TG/TT individuals do diverge somewhat below the 50th percentile of blood lead. The relatively small number of TG/TT individuals in this range makes it difficult to meaningfully interpret this finding.
In conclusion, in this study, no evidence for associations of the T 894 allele with systolic blood pressure, diastolic blood pressure, or hypertension was observed. There also was no evidence for effect modification by the allele of the relation between lead and blood pressure. Given the uncertainties about the role of this polymorphism in NO production, and the effect of lead on the NO system, the negative findings of this study do not rule out an effect of lead on NO production or a role for decreased NO production in hypertension.
